NEWS CENTER

Position:

Group Announcement

Media reports

Group News

Shi Si Pharmaceutical Group Delivers an Excellent Interim Report.

Category:

Group News

Time：2021-08-27

Shi Si Pharmaceutical Group Delivers an Excellent Interim Report.

Faced with the severe challenges posed by the ongoing COVID-19 pandemic both domestically and internationally, in the first half of this year, Shisi Pharmaceutical Group adopted a multi-pronged approach to drive innovation and safeguard its market position. The group has been promoting synergistic development across the entire pharmaceutical value chain—from pharmaceutical packaging materials and active pharmaceutical ingredients to high-end formulations and diverse dosage forms—while continuously launching new products and obtaining approvals for previously reviewed drug varieties. As a result, the company’s market advantages have continued to expand, enabling it to effectively counter the various adverse impacts brought about by the pandemic and deliver an outstanding performance. According to its interim report, the company achieved a 37% year-on-year increase in sales revenue and an 11.6% year-on-year rise in net profit during the first half of the year, and once again ranked among the Top 100 Chinese pharmaceutical companies and the Top 30 Chinese enterprises with the best pharmaceutical R&D pipelines.

In the first half of the year, Shiyao Group focused its efforts on enhancing its core business through market-entry initiatives, optimizing product structures, refining business segments, and highlighting distinctive new products. The company actively implemented measures aimed at achieving breakthroughs in the market share of both newly launched formulations and active pharmaceutical ingredients.

Taking the national centralized procurement and provincial and regional volume-based procurement initiatives as opportunities, we are continuously expanding the market accessibility of our group’s products. In the first half of the year, four products—ambrisol hydrochloride injection, doxofylline injection, fluconazole sodium chloride injection, and ropivacaine hydrochloride injection—in six specifications were selected in the fourth and fifth rounds of the national drug centralized procurement. As of now, Shisi Pharmaceutical Group has had six products in nine specifications included in the national drug centralized procurement, creating favorable conditions for accelerating the shift from regional market development to nationwide, coordinated product development.

The new product lineup has delivered outstanding performance, particularly the ampoule series, which has become a key growth driver for the company’s injectable solutions segment. While ampoule products such as Betahistine Hydrochloride Injection, Bromhexine Hydrochloride Injection, and Terbutaline Sulfate Solution for Nebulization are accelerating their market expansion, three additional ampoule products—Ambroxol Hydrochloride Injection, Doxofylline Injection, and Ropivacaine Hydrochloride Injection—have successively been included in the national centralized procurement program, serving as a new pivotal force for the group’s ampoule products to achieve rapid scale breakthroughs. In the first half of the year, sales of ampoule products reached RMB 406.49 million, representing a 53% increase and maintaining a strong momentum of high-speed growth.

The production and sales of active pharmaceutical ingredients (APIs) continue to gain momentum. Through continuous optimization and upgrading of production processes, as well as the renovation and enhancement of environmental protection capabilities, production capacity has been rapidly released. Bulk APIs are now being exported extensively to markets in South America, Europe, Asia, and other regions. The pace of industrialization for specialty APIs such as lurasidone hydrochloride, linezolid, and terbutaline sulfate has accelerated, making them a key growth potential for the group’s development.

The supporting capabilities of pharmaceutical packaging materials and the upstream and downstream industrial chain continue to strengthen. A multi-layer co-extruded biofilm for single-use fluid preparation systems, compliant with USP Class VI standards and relevant national standards, has been put into industrial-scale production. These products are widely used in the research and development and manufacturing of vaccines and biopharmaceuticals. Currently, this company is the only domestic manufacturer capable of replacing imported biofilms, and it boasts a promising market outlook.

The intensity and gradient of innovation are steadily intensifying, and the product lineup is becoming increasingly diverse, providing a powerful engine for the company’s high-quality development. Building on collaborations with numerous “Double First-Class” universities and research institutions, in June of this year, the company also reached a strategic cooperation agreement with China Pharmaceutical University. By establishing a new drug R&D technology platform that integrates industry, academia, and research, we will promote scientific and technological innovation and accelerate the industrialization of scientific and technological achievements.

Combining current and potential market demands, Shiyao Group remains firmly committed to advancing the research and development of innovative drugs, generic drugs, and consistency evaluation studies for generic drugs. Its first-in-class innovative drug candidate, NP-01, has entered Phase I clinical trials, while other innovative drugs such as AND-9—a novel drug for the treatment of liver fibrosis—have accelerated their early-stage research. The group has achieved remarkable results in consistency evaluation studies; to date, 15 drug varieties comprising 20 specifications have either passed or been deemed to have passed the consistency evaluation. In the first half of the year, the group obtained a total of 7 production approvals across various categories. Currently, Shiyao Group has submitted a cumulative total of 61 new product projects, including 35 liquid and solid dosage forms, 13 products undergoing consistency evaluation, and 13 active pharmaceutical ingredients. With steadily accumulating achievements in innovation, the group is now well-positioned to drive a significant transformation in its production and sales structure, building up ample momentum for future growth.

Keywords:

A Heartfelt Initiative Honors Teacher’s Day: Shijiazhuang Fourth Pharmaceutical’s Public Welfare Campaign Visits Xibaipo Hope Primary School.

Let’s set off again! The grand summary conference on R&D and innovation achievements of Shisi Pharmaceutical Group was held with great ceremony.

A Heartfelt Initiative Honors Teacher’s Day: Shijiazhuang Fourth Pharmaceutical’s Public Welfare Campaign Visits Xibaipo Hope Primary School.

Let’s set off again! The grand summary conference on R&D and innovation achievements of Shisi Pharmaceutical Group was held with great ceremony.